TruScreen raises $1.6 mln in share purchase plan
TruScreen raises $1.6 mln in oversubscribed share purchase plan
By Paul McBeth
July 1
(BusinessDesk) - TruScreen, the NZAX-listed cervical cancer
test developer, raised $1.56 million in an oversubscribed
share purchase plan to help fund its push into Asia.
The Auckland-based company was seeking $1 million through the share purchase plan, but accepted all subscriptions, it said in a statement. The share sale was at 25 cents apiece and accounted for 3.8 percent of shares on issue. The shares last traded at 26 cents.
The share purchase plan was
one of two capital raising initiatives, the other being a
placement to institutional and professional investors,
injecting $4.83 million in total.
"We view these two
capital raising initiatives as a dual validation of our
commercial strategy by both our institutional and retail
investors," chief executive Martin Dillon said. "The new
capital raised form these initiatives gives us the ability
to continue our expansion of the commercial operations of
TruScreen, and build on the extensive success we have had in
the past year with our international growth."
Last
month, TruScreen reported an annual loss of $692,000 on
revenue of $1.57 million. The company has had several
breakthroughs in the Chinese market, securing certification
from the Chinese Food and Drug Administration and Thailand's
Food and Drug Administration and signing two deals that are
expected to generate almost $2 million in revenue over the
next 14 months.
(BusinessDesk)